According to researchers, a form of inflammation called neuroinflammation may contribute to certain cases of Autism Spectrum Disorder (ASD). Cells derived from umbilical cords called mesenchymal stromal cells (MSCs) may be advantageous to affected individuals. In a study of children who were treated with MSCs, neuroinflammation was reduced in 6 out of 12 cases. As a result, at least 2 autism-related triggers were improved in these individuals.
The experiment used an IV to infuse the MSCs. Before proceeding forward, researchers ensured that the particular strands of MSCs chosen were safe for administration to children. The children were aged 4 to 9 and were given either one, two, or three doses of MSCs over the course of 2 months. Afterwards, the children were evaluated for the next year.
Overall, this exciting new research could prove beneficial to the ASD community as a whole. The clinical trials will proceed to phase II testing in the months to come.